Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States [0.03%]
美国住院患者中种族差异导致浆细胞白血病预后不良
Cindy Wu,Deepa Dongarwar,Samer Al Hadidi
Cindy Wu
Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients' outcomes. In this study...
Standing on the Shoulders of the Giants: Dr. Alain Fischer [0.03%]
站在巨人的肩膀上——献给阿尔明·夏尔教授及菲利普·亨利·斯塔宾斯博士的文章之阿兰·菲舍尔教授
Mohamad Mohty,Alain Fischer
Mohamad Mohty
Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand? [0.03%]
鲁索利替尼在难治/复发霍奇金淋巴瘤治疗中的应用：我们目前处于什么阶段？
Ahmed H Al Sharie,Balqis M Abu Mousa,Ahmad O Alomari
Ahmed H Al Sharie
Marwa Alhamss,Riad El Fakih
Marwa Alhamss
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma [0.03%]
多发性骨髓瘤当前正在入组的维持治疗临床试验的景观分析
Syed Maaz Tariq,Al-Ola Abdallah,Aaron Goodman et al.
Syed Maaz Tariq et al.
Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy being employed in currently enrolling clinical trials for patients with multiple myeloma a...
Thromboembolism Early After Glucocorticoid Administration in Patients with Autoimmune Hemolytic Anemia [0.03%]
自身免疫性溶血性贫血患者接受糖皮质激素治疗早期的血栓栓塞事件
Kohei Shiroshita,Mikio Okayama,Hiroki Soma et al.
Kohei Shiroshita et al.
Pulmonary embolism and deep venous thrombosis (PE/DVT) are well-known lethal complications in autoimmune hemolytic anemia (AIHA). However, the impact of their treatment is unclear. Here, we describe three elderly Japanese patients with AIHA...
Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia [0.03%]
沙特阿拉伯单中心慢性淋巴细胞白血病患者的临床和细胞遗传学特征及预后分析
Areej Al Mugairi,Ekremah Alzarea,Abdulaziz Almosa et al.
Areej Al Mugairi et al.
Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature [0.03%]
布加替尼联合大剂量化疗及异基因造血干细胞移植治疗难治性间变性大细胞淋巴瘤1例及文献复习
Giulia Caddeo,Cristina Tecchio,Matteo Chinello et al.
Giulia Caddeo et al.
The treatment of pediatric patients with refractory or relapsed anaplastic large cell lymphoma (ALCL) is still a major challenge. In addition to conventional chemotherapy and stem cell transplantation, new therapeutic options such as anti-C...
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome [0.03%]
维奈托克在急性髓系白血病和骨髓增生异常综合征新型治疗时代的应用伙伴疗法作用机制及研究进展
Jean El-Cheikh,Ghassan Bidaoui,Mustafa Saleh et al.
Jean El-Cheikh et al.
Background: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are two closely related blood cancers that are more frequent in older adults. AML is the most common type of adult acute leukemia, and MDS is cha...
Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH) [0.03%]
国际血液学临床学院(IMS 2022研讨会后 round table 辩论)关于多发性骨髓瘤的最新进展
Nizar J Bahlis,Luciano J Costa,Thierry Facon et al.
Nizar J Bahlis et al.
This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th A...